The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery to normal level is associated with a significant improvement in overall ...

(UroToday.com) The 2025 ASTRO annual meeting featured a predictive markers in prostate cancer session and a presentation by Dr. Melvin L. K. Chua discussing validation of a prognostic multimodal ...

The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade tumors. There was an observed nearly 20-fold increase in the presence of ...

Primary physician reporting grade 2+ toxicity per CTCAE version 5.0 was the primary endpoint. Follow-up was performed 30 days post-treatment and subsequently every 3 to 4 months for 2 years: ...

Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

No patients died of prostate cancer. The 5-year overall survival was 90%.

A total of 295 eligible patients were enrolled with a median follow-up of 5.0 years. The arms were well balanced, with a ...

The U54 ROBIN consortium is a first-of-its-kind effort to study the biological effects of radiation before, during, and after treatment, using small study cohorts for detailed molecular ...